Chimeric Therapeutics Limited
CHMMF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | 72.2% | – |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | 78.7% | – | 100% | 63.7% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -228.7% | – | -533% | -520.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -262.8% | – | -566% | -607.5% |
| EPS Diluted | -0.008 | -0.018 | -0.059 | -0.044 |
| % Growth | 57.2% | 69.4% | -33.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |